Every Form 4 that Nasus Pharma Ltd. (NSRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NSRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NSRX filings page.
Nasus Pharma Ltd disclosed that Dan Benjamin Teleman has ceased to serve as Chief Executive Officer and resigned as a director on the Board of Directors, effective July 22, 2026. As a result, he is no longer subject to Section 16 reporting obligations regarding Nasus Pharma securities.
Nasus Pharma Ltd Chief Executive Officer and director Dan Benjamin Teleman reported an open-market purchase of 6,550 Ordinary Shares at $3.10 per share. Following this transaction, he directly owns 163,541 Ordinary Shares in total. This holding includes 30,696 Ordinary Shares and 132,845 additional Ordinary Shares that are issuable from share options exercisable within 60 days, highlighting a meaningful option-based exposure alongside his common share position.
Nasus Pharma Ltd Chief Executive Officer Dan Benjamin Teleman reported an open-market purchase of 2,900 Ordinary Shares of NSRX at $3.76 per share on April 22, 2026. After this transaction, he beneficially owns 156,991 shares in total.
This position consists of 24,146 Ordinary Shares and 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days, indicating that the trade is small relative to his overall economic exposure to the company.
Nasus Pharma Ltd Chief Executive Officer Dan Benjamin Teleman reported an open-market purchase of 15,000 Ordinary Shares of the company at $2.04 per share. Following this transaction, he directly holds 21,246 Ordinary Shares, indicating a higher personal equity stake in the business.